Drug intelligence / Profile preview

HXLMT026

Development stage: Unknown
Lead developer: Hunan Huize Biopharmaceutical Technology
Modality: Small Molecules
Administration: Oral

Overview

HXLMT026 is an investigational small molecule melatonin receptor agonist developed by Hunan Huize Biopharmaceutical Technology for the treatment of insomnia disorder, specifically targeting sleep-onset difficulty. It is currently being evaluated in Phase I clinical trials in China to determine its pharmacokinetics and relative bioavailability compared to ramelteon (Rozerem) tablets. As a melatonin receptor agonist, HXLMT026 likely targets the MT1 and MT2 receptors in the suprachiasmatic nucleus of the hypothalamus, which are involved in the regulation of the sleep-wake cycle and the promotion of sleep onset.

Targets

MTNR1B (Melatonin Receptor 2)MTNR1A (MT1)

Beyond the preview

Go deeper on HXLMT026.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HXLMT026.

Explore the full profile